Daiichi Sankyo Expands its Collaboration with Esperion to Additional Territories

 Daiichi Sankyo Expands its Collaboration with Esperion to Additional Territories

Daiichi Sankyo Expands its Collaboration with Esperion to Additional Territories

Shots:

  • Esperion to receive $30M up front, ~$175M as sales milestones along with royalties from 5-20% on sales in the territory. Daiichi Sankyo will get exclusive commercialization rights to bempedoic acid and bempedoic acid/ezetimibe combination tablet in S. Korea, Taiwan, Hong Kong, Thailand, Vietnam, Brazil, Macao, Cambodia, and Myanmar
  • The agreement allows for the expansion across geographies in Asia, the Middle East and Latin America. While Daiichi Sankyo holds commercialization rights in these territories, the rights for development and regulatory activities will remain with Esperion
  • With this deal, combined milestones from the Daiichi Sankyo now total over $1.1B

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: BioSpace

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post